Open an account

Johnson & Johnson

JNJ · NYSE

$259.36+$5.57 (+2.19%)TodayMarket closed ·
Prev close $253.79

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Employees
138,200
Headquarters
New Brunswick, New Jersey
Listed
Sep 25, 1944
Sector
Health Care
Industry
Pharmaceuticals
Website
jnj.com

JNJ key statistics

Market cap
625.03B
Price-earnings ratio
29.44
Dividend yield
2.02%
Average volume
7.41M
Volume
7.66M
Open price
$257.48
High today
$260.77
Low today
$256.42
52 Week high
$281.07
52 Week low
$184.66

Johnson & Johnson (JNJ) at a glance

As of Oct 20, 2026, Johnson & Johnson (JNJ) shares are priced at $259.36, giving the company a market cap of 625.03B, a price-to-earnings ratio of 29.44 and a dividend yield of 2.02%.

Today the stock has traded between $256.42 and $260.77. The current price is 1.1% above the day's low and 0.5% below its high.

Volume so far is 7.66M shares, in line with the average of 7.41M shares a day.

Over the past year Johnson & Johnson has ranged from $184.66 to $281.07, and now sits 77% of the way up that range.

Johnson & Johnson met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY26 it reported $2.59 per share against an estimate of $2.56.

The average analyst price target is $280.25, 8.1% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 21 analyst ratings say Buy
  • Buy71.4%
  • Hold28.6%
  • Sell0.0%
Price target · 27 analystsAvg $280.25
Low
$171.70
Now
$259.36
High
$336.00

JNJ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 1.7% on average.

  1. Q4 FY24: reported $2.04 per share against an estimate of $2.03
  2. Q1 FY25: reported $2.77 per share against an estimate of $2.61
  3. Q2 FY25: reported $2.77 per share against an estimate of $2.71
  4. Q3 FY25: reported $2.80 per share against an estimate of $2.78
  5. Q4 FY25: reported $2.46 per share against an estimate of $2.46
  6. Q1 FY26: reported $2.70 per share against an estimate of $2.69
  7. Q2 FY26: reported $2.90 per share against an estimate of $2.87
  8. Q3 FY26: reported $2.59 per share against an estimate of $2.56

JNJ news

  • Press releaseBusiness Wire

    Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half

  • Press releasePRNewswire

    Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

  • Press releaseBusiness Wire

    JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law

  • Press releasePRNewswire

    Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

  • Priya Nigam

    Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

  • Shivdeep Dhaliwal

    Bank of America, Johnson & Johnson, Six Flags Entertainment, Citigroup and Applied Materials: Why These 5 Stocks Are on Investors' Radars Today

  • Vandana Singh

    Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

Similar companies

Companies in the same industry as Johnson & Johnson

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.